Dabrafenib/trametinib is the first and only BRAF/MEK inhibitor combination to be approved with a tumor-agnostic indication for solid tumors carrying the BRAF V600E mutation A U.S. FDA drug approval ...
The treatment of newly diagnosed multiple myeloma (NDMM) has evolved significantly in recent years with the introduction of quadruplet regimens, which typically combine an anti-CD38 monoclonal ...
Summaries of recently published ECOG-ACRIN research results ...
EA8192 – A Phase II/III trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy The study chair for this trial is Jean ...
Classical Hodgkin lymphoma (cHL) is an aggressive disease that develops in the lymphatic system, part of the immune system. It can develop at any age but occurs most frequently in two age groups: ...
EAQ241CD – Addressing Financial Hardship in AYA Cancer Survivors: Efficacy and Implementation of a Multilevel Intervention (LIFT UP) in Community-Based Oncology Practices Individuals diagnosed with ...
Pancreatic cysts are a common and often incidental finding on abdominal imaging. These cysts are important to monitor because a minority of them will transform into pancreatic cancer over time. The ...
The study chair for this trial is Shaji Kumar, MD (Mayo Clinic). The study co-chairs are Ajay Nooka, MD, MPH (Emory University/Winship Cancer Institute), Lale Kostakoglu, MD, MPH (University of ...
Now Enrolling: EA8231 Study for Patients With Bladder Cancer That Has Progressed Following Treatment
A Phase III Randomized Trial of Pembrolizumab in Combination with Sacituzumab Govitecan vs. Standard of Care in Anti-PD(L)1-Resistant Advanced Urothelial Cancer Bladder cancer (urothelial carcinoma) ...
Below are the titles for a number of ECOG-ACRIN-related analyses published since our last Research Round-Up post in August 2023. Click on the shortened citation to access the publication.
ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and the other national cancer cooperative groups have partnered with Conquer Cancer®, the ASCO Foundation and Bristol Myers Squibb to support a new ...
The study co-chairs for this trial are Leon Lenchik, MD (Wake Forest University Health Sciences), Robert Boutin, MD (Stanford Cancer Institute), and Xin Yao, MD (ThedaCare Regional Cancer Center).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results